| Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ... New England Journal of Medicine 361 (2), 123-134, 2009 | 4299 | 2009 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1591 | 2017 |
| Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ... Journal of clinical oncology 28 (15), 2512-2519, 2010 | 1108 | 2010 |
| Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate AHM Reid, G Attard, DC Danila, NB Oommen, D Olmos, PC Fong, ... Journal of clinical oncology 28 (9), 1489, 2010 | 512 | 2010 |
| Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience D Olmos, HT Arkenau, JE Ang, I Ledaki, G Attard, CP Carden, AHM Reid, ... Annals of oncology 20 (1), 27-33, 2009 | 280 | 2009 |
| A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors SK Sandhu, K Papadopoulos, PC Fong, A Patnaik, C Messiou, D Olmos, ... Cancer chemotherapy and pharmacology 71, 1041-1050, 2013 | 270 | 2013 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 248 | 2019 |
| Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor JS De Bono, G Attard, A Adjei, MN Pollak, PC Fong, P Haluska, L Roberts, ... Clinical Cancer Research 13 (12), 3611-3616, 2007 | 203 | 2007 |
| Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) LR Molife, G Attard, PC Fong, V Karavasilis, AHM Reid, S Patterson, ... Annals of oncology 21 (1), 109-113, 2010 | 192 | 2010 |
| Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ... Journal of the American College of Cardiology 73 (4), 387-396, 2019 | 190 | 2019 |
| Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with … JS de Bono, R Kristeleit, A Tolcher, P Fong, S Pacey, V Karavasilis, ... Clinical Cancer Research 14 (20), 6663-6673, 2008 | 134 | 2008 |
| Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors SJ Moschos, RJ Sullivan, WJ Hwu, RK Ramanathan, AA Adjei, PC Fong, ... JCI insight 3 (4), 2018 | 129 | 2018 |
| Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial N Agarwal, AA Azad, J Carles, AP Fay, N Matsubara, D Heinrich, ... The Lancet 402 (10398), 291-303, 2023 | 122 | 2023 |
| Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised … F Saad, K Fizazi, V Jinga, E Efstathiou, PC Fong, LL Hart, R Jones, ... The Lancet Oncology 16 (3), 338-348, 2015 | 115 | 2015 |
| 5, 6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent MJ McKeage, P Fong, M Jeffery, BC Baguley, P Kestell, M Ravic, ... Clinical cancer research 12 (6), 1776-1784, 2006 | 111 | 2006 |
| AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I … PC Fong, DS Boss, CP Carden, M Roelvink, J De Greve, CM Gourley, ... Journal of Clinical Oncology 26 (15_suppl), 5510-5510, 2008 | 108 | 2008 |
| The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose … LR Molife, PC Fong, L Paccagnella, AHM Reid, HM Shaw, L Vidal, ... British journal of cancer 103 (3), 332-339, 2010 | 104 | 2010 |
| Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled … JA Ledermann, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet Oncology 21 (5), 710-722, 2020 | 101 | 2020 |
| Active fixation lead with multiple density S Salys, P Fong, PD Doan US Patent 7,092,766, 2006 | 99 | 2006 |
| Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors I Ray-Coquard, J Brown, P Harter, DM Provencher, PC Fong, J Maenpaa, ... International Journal of Gynecologic Cancer 24 (Supp 3), 2014 | 96 | 2014 |
